Target enrollment complete in Phase 1b trial of GT-02287
Target enrollment is complete for a Phase 1b trial testing the safety and tolerability of GT-02287 in people with Parkinson’s disease.| Parkinson's News Today
Target enrollment is complete for a Phase 1b trial testing the safety and tolerability of GT-02287 in people with Parkinson’s disease.| Parkinson's News Today
